Filing Flows › Sutro Biopharma (STRO) › Q2 2026
Sutro Biopharma (STRO) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 12, 2026
Sutro Biopharma (STRO) reported revenue of $9.8M for the second quarter 2026 (Q2 2026), -85% from a year earlier and -32% from the quarter before. Operating margin was -303.8%, net loss $38.5M (391.6% of revenue).
Sutro Biopharma, Q2 2026: revenue $9.8M (-85% year over year), operating margin -303.8%, net loss $38.5M, operating cash flow −$38.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.8M | -32% | -85% |
| Operating profit | −$29.9M | — | — |
| Net earnings | −$38.5M | — | — |
| Operating cash flow | −$38.3M | — | — |
What changed
Revenue was $9.8M in Q2 2026, down 85% year over year and down 32% from the previous quarter.
Operating costs exceeded revenue by $29.9M, an operating margin of -303.8%. Total costs fell 41% while revenue fell 85%. The quarter ended with a net loss of $38.5M, wider than the previous quarter's $38.5M loss.
Operating cash flow was −$38.3M. Non-cash charges added back $1.3M of depreciation and amortization and $2.0M of share-based compensation. Working capital and other items used $3.0M.
Questions
What was Sutro Biopharma's revenue in the second quarter 2026?
Sutro Biopharma (STRO) reported revenue of $9.8M for the second quarter 2026 (Q2 2026), -85% from a year earlier and -32% from the quarter before.
Was Sutro Biopharma profitable in the second quarter 2026?
Operating loss was $29.9M (-303.8% of revenue) and net loss $38.5M.
Source: Sutro Biopharma 10-Q on SEC EDGAR.